{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:06:24Z","timestamp":1785895584340,"version":"3.56.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T00:00:00Z","timestamp":1456963200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s40256-016-0165-4","type":"journal-article","created":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T11:52:00Z","timestamp":1457005920000},"page":"255-266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?"],"prefix":"10.1007","volume":"16","author":[{"given":"Csaba Andr\u00e1s","family":"D\u00e9zsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,3]]},"reference":[{"issue":"5","key":"165_CR1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507\u201320.","journal-title":"JAMA."},{"issue":"31","key":"165_CR2","first-page":"1281","volume":"2013","author":"The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology","year":"2013","unstructured":"The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. ESH\/ESC Guidelines for the management of arterial hypertension. J Hypertens. 2013;2013(31):1281\u2013357.","journal-title":"J Hypertens"},{"issue":"6","key":"165_CR3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jash.2015.03.002","volume":"9","author":"C Rosendorff","year":"2015","unstructured":"Rosendorff C, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Soc Hypertens. 2015;9(6):453\u201398.","journal-title":"J Am Soc Hypertens."},{"key":"165_CR4","volume-title":"Cardiovascular diseases: from molecular pharmacology to evidence-based therapeutics","author":"Robert Li","year":"2015","unstructured":"Li Robert. Cardiovascular diseases: from molecular pharmacology to evidence-based therapeutics. Hoboken: Wiley.; 2015."},{"issue":"1","key":"165_CR5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2147\/vhrm.2008.04.01.89","volume":"4","author":"R Negro","year":"2008","unstructured":"Negro R. Endothelial effects of antihypertensive treatment: focus on irbesartan. Vasc Health Risk Manag. 2008;4(1):89\u2013101.","journal-title":"Vasc Health Risk Manag."},{"issue":"1","key":"165_CR6","first-page":"92","volume":"69","author":"T Aoyama","year":"2011","unstructured":"Aoyama T, Minatoguchi S. The effect of ARB on prevention of atherosclerosis. Nihon Rinsho. 2011;69(1):92\u20139.","journal-title":"Nihon Rinsho."},{"key":"165_CR7","doi-asserted-by":"crossref","unstructured":"Carey RM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension. 2000;35[part 2]:155\u201363.","DOI":"10.1161\/01.HYP.35.1.155"},{"issue":"9395","key":"165_CR8","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","volume":"362","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2003","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527\u201335.","journal-title":"Lancet."},{"key":"165_CR9","unstructured":"https:\/\/www.medicines.org.uk\/emc\/"},{"key":"165_CR10","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"The ONTARGET Investigators","year":"2008","unstructured":"The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547\u201359.","journal-title":"N Engl J Med"},{"key":"165_CR11","doi-asserted-by":"crossref","unstructured":"TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174\u201383.","DOI":"10.1016\/S0140-6736(08)61242-8"},{"issue":"9644","key":"165_CR12","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S0140-6736(08)61243-X","volume":"372","author":"TL Ripley","year":"2008","unstructured":"Ripley TL. The power to TRANSCEND. Lancet. 2008;372(9644):1128\u201330.","journal-title":"Lancet."},{"issue":"4","key":"165_CR13","first-page":"240","volume":"57","author":"AJ Scheen","year":"2002","unstructured":"Scheen AJ. Clinical study of the month. The LIFE study: cardiovascular protection of hypertensive patients by losartan. Rev Med Liege. 2002;57(4):240\u20134.","journal-title":"Rev Med Liege."},{"issue":"1","key":"165_CR14","first-page":"57","volume":"57","author":"L Pi\u00e9rard","year":"2002","unstructured":"Pi\u00e9rard L. Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study. Rev Med Liege. 2002;57(1):57\u20139.","journal-title":"Rev Med Liege."},{"key":"165_CR15","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","volume":"100","author":"RS McKelvie","year":"1999","unstructured":"McKelvie RS, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation. 1999;100:1056\u201364.","journal-title":"Circulation"},{"issue":"9386","key":"165_CR16","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","volume":"362","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer MA, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759\u201366.","journal-title":"Lancet."},{"issue":"9054","key":"165_CR17","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","volume":"349","author":"B Pitt","year":"1997","unstructured":"Pitt B, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349(9054):747\u201352.","journal-title":"Lancet."},{"issue":"9215","key":"165_CR18","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","volume":"355","author":"B Pitt","year":"2000","unstructured":"Pitt B, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2013the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582\u20137.","journal-title":"Lancet."},{"issue":"9704","key":"165_CR19","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","volume":"374","author":"MA Konstam","year":"2009","unstructured":"Konstam MA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374(9704):1840\u20138.","journal-title":"Lancet."},{"key":"165_CR20","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1161\/CIRCULATIONAHA.104.508093","volume":"111","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, et al. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation. 2005;111:3411\u20139.","journal-title":"Circulation."},{"issue":"4","key":"165_CR21","first-page":"159","volume":"4","author":"T Noro","year":"2014","unstructured":"Noro T, et al. Initial reduction of oxidative stress by angiotensin receptor blocker contributes long term outcomes after percutaneous coronary intervention. Am J Cardiovasc Dis. 2014;4(4):159\u201367.","journal-title":"Am J Cardiovasc Dis."},{"issue":"6","key":"165_CR22","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/HJH.0000000000000154","volume":"32","author":"S Foulquier","year":"2014","unstructured":"Foulquier S, et al. Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis. J Hypertens. 2014;32(6):1334\u201341.","journal-title":"J Hypertens."},{"issue":"3","key":"165_CR23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1524-6175.2005.04254.x","volume":"7","author":"SE Kjeldsen","year":"2005","unstructured":"Kjeldsen SE, et al. The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. J Clin Hypertens (Greenwich). 2005;7(3):152\u20138.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"12","key":"165_CR24","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","volume":"359","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359(12):1225\u201337.","journal-title":"N Engl J Med."},{"issue":"5","key":"165_CR25","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1097\/01.hjh.0000357906.60778.7f","volume":"27","author":"HC Diener","year":"2009","unstructured":"Diener HC. Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs. J Hypertens Suppl. 2009;27(5):S31\u20136.","journal-title":"J Hypertens Suppl."},{"issue":"6","key":"165_CR26","first-page":"1175","volume":"44","author":"V Papademetriou","year":"2004","unstructured":"Papademetriou V, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004;44(6):1175\u201380.","journal-title":"J Am Coll Cardiol."},{"key":"165_CR27","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1161\/01.STR.0000075777.18006.89","volume":"34","author":"J Schrader","year":"2003","unstructured":"Schrader J, et al. The ACCESS Study. Evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke. 2003;34:1699\u2013703.","journal-title":"Stroke."},{"key":"165_CR28","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/01.STR.0000166048.35740.a9","volume":"36","author":"J Schrader","year":"2005","unstructured":"Schrader J, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218\u201326.","journal-title":"Stroke."},{"key":"165_CR29","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2004.10.068","volume":"45","author":"K Wachtell","year":"2005","unstructured":"Wachtell K, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"165_CR30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ahj.2005.06.036","volume":"152","author":"A Ducharme","year":"2006","unstructured":"Ducharme A, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006;152:86\u201392.","journal-title":"Am Heart J"},{"key":"165_CR31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/HJH.0b013e3282f35c67","volume":"26","author":"R Schmieder","year":"2008","unstructured":"Schmieder R, et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens. 2008;26:403\u201311.","journal-title":"J Hypertens"},{"key":"165_CR32","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ahj.2004.09.033","volume":"149","author":"A Maggioni","year":"2005","unstructured":"Maggioni A, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149:548\u201357.","journal-title":"Am Heart J"},{"key":"165_CR33","doi-asserted-by":"crossref","unstructured":"Takii E, et al. Beneficial effects of losartan for prevention of paroxysmal atrial fibrillation in patients with sick sinus syndrome: analysis with memory function of pacemaker. Heart Vessels. 2015 [Epub ahead of print].","DOI":"10.1007\/s00380-015-0627-7"},{"issue":"1","key":"165_CR34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1074248410395018","volume":"17","author":"R Fogari","year":"2012","unstructured":"Fogari R, et al. Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. J Cardiovasc Pharmacol Ther. 2012;17(1):34\u201343.","journal-title":"J Cardiovasc Pharmacol Ther."},{"issue":"6","key":"165_CR35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/clc.21994","volume":"35","author":"R Fogari","year":"2012","unstructured":"Fogari R, et al. Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size. Clin Cardiol. 2012;35(6):359\u201364.","journal-title":"Clin Cardiol."},{"issue":"Suppl 2","key":"165_CR36","first-page":"556","volume":"116","author":"D Galzerano","year":"2007","unstructured":"Galzerano D, et al. A multicentre, randomized study comparing efficacy of telmisartan versus carvedilol in preventing atrial fibrillation recurrence in hypertensive patients. Circulation. 2007;116(Suppl 2):556\u20137.","journal-title":"Circulation"},{"issue":"1","key":"165_CR37","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/01.fjc.0000193808.99773.28","volume":"47","author":"R Fogari","year":"2006","unstructured":"Fogari R, Mugellini A, Destro M, et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol. 2006;47(1):46\u201350.","journal-title":"J Cardiovasc Pharmacol."},{"issue":"3","key":"165_CR38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/FJC.0b013e318160b42a","volume":"51","author":"R Fogari","year":"2008","unstructured":"Fogari R, Zoppi A, Mugellini A, et al. Comparative evaluation of effect of valsartan\/amlodipine and atenolol\/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. J Cardiovasc Pharmacol. 2008;51(3):217\u201322.","journal-title":"J Cardiovasc Pharmacol."},{"issue":"9","key":"165_CR39","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/ajh.2008.217","volume":"21","author":"R Fogari","year":"2008","unstructured":"Fogari R, et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J Hypertens. 2008;21(9):1034\u20139.","journal-title":"Am J Hypertens."},{"issue":"16","key":"165_CR40","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJMoa0805710","volume":"360","author":"M Disertori","year":"2009","unstructured":"Disertori M, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360(16):1606\u201317.","journal-title":"N Engl J Med."},{"key":"165_CR41","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/01.CIR.0000022665.18619.83","volume":"106","author":"AH Madrid","year":"2002","unstructured":"Madrid AH, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. a prospective and randomized study. Circulation. 2002;106:331\u20136.","journal-title":"Circulation."},{"issue":"10","key":"165_CR42","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1008816","volume":"364","author":"S Yusuf","year":"2011","unstructured":"Yusuf S, et al. Irbesartan in patients with atrial fibrillation. N Engl J Med. 2011;364(10):928\u201338.","journal-title":"N Engl J Med."},{"issue":"1","key":"165_CR43","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s13063-015-0836-5","volume":"16","author":"WW Qi","year":"2015","unstructured":"Qi WW, et al. Upstream therapeutic strategies of valsartan and fluvastatin on hypertensive patients with non-permanent atrial fibrillation (VF-HT-AF): study protocol for a randomized controlled trial. Trials. 2015;16(1):336.","journal-title":"Trials."},{"issue":"12","key":"165_CR44","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.tips.2011.07.006","volume":"32","author":"JM Luther","year":"2011","unstructured":"Luther JM, Brown NJ. The renin-angiotensin-aldosterone system and glucose homeostasis. Trends Pharmacol Sci. 2011;32(12):734\u20139.","journal-title":"Trends Pharmacol Sci."},{"issue":"7","key":"165_CR45","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1463-1326.2012.01559.x","volume":"14","author":"NJ Zijl van der","year":"2012","unstructured":"van der Zijl NJ, et al. Does interference with the renin-angiotensin system protect against diabetes? Evidence and mechanisms. Diabetes Obes Metab. 2012;14(7):586\u201395.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"165_CR46","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.diabres.2010.04.018","volume":"89","author":"U Kintscher","year":"2010","unstructured":"Kintscher U, et al. Effect of high-dose valsartan on inflammatory and lipid parameters in patients with type 2 diabetes and hypertension. Diabetes Res Clin Pract. 2010;89(3):209\u201315.","journal-title":"Diabetes Res Clin Pract."},{"key":"165_CR47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1475-2840-13-91","volume":"13","author":"CH Chang","year":"2014","unstructured":"Chang CH, et al. Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study. Cardiovasc Diabetol. 2014;13:91.","journal-title":"Cardiovasc Diabetol."},{"issue":"12","key":"165_CR48","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1463-1326.2011.01471.x","volume":"13","author":"M Zhao","year":"2011","unstructured":"Zhao M, et al. Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. Diabetes Obes Metab. 2011;13(12):1123\u20139.","journal-title":"Diabetes Obes Metab."},{"key":"165_CR49","unstructured":"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02079805"},{"issue":"3","key":"165_CR50","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2710.2011.01295.x","volume":"37","author":"N Suksomboon","year":"2012","unstructured":"Suksomboon N, et al. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes. J Clin Pharm Ther. 2012;37(3):319\u201327.","journal-title":"J Clin Pharm Ther."},{"issue":"5","key":"165_CR51","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/ajh.2011.8","volume":"24","author":"G Tocci","year":"2011","unstructured":"Tocci G. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials. Am J Hypertens. 2011;24(5):582\u201390.","journal-title":"Am J Hypertens."},{"issue":"7","key":"165_CR52","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.amjcard.2006.10.068","volume":"99","author":"R Andraws","year":"2007","unstructured":"Andraws R, et al. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol. 2007;99(7):1006\u201312.","journal-title":"Am J Cardiol."},{"key":"165_CR53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/sj.jhh.1001931","volume":"20","author":"BMY Cheung","year":"2006","unstructured":"Cheung BMY, et al. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. J Hum Hypertens. 2006;20:37\u201343.","journal-title":"J Hum Hypertens"},{"key":"165_CR54","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/hr.2009.135","volume":"32","author":"TW Kurtz","year":"2009","unstructured":"Kurtz TW, Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens Res. 2009;32:826\u201334.","journal-title":"Hypertens Res"},{"issue":"12","key":"165_CR55","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1503\/cmaj.121771","volume":"185","author":"T Antoniou","year":"2013","unstructured":"Antoniou T, et al. Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. CMAJ. 2013;185(12):1035\u201341.","journal-title":"CMAJ."},{"key":"165_CR56","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJM199811123392007","volume":"339","author":"G Remuzzi","year":"1998","unstructured":"Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998;339:1448\u201356.","journal-title":"N Engl J Med"},{"key":"165_CR57","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/S0140-6736(00)04728-0","volume":"357","author":"P Ruggenenti","year":"2001","unstructured":"Ruggenenti P, et al. Progression, remission, regression of chronic renal diseases. Lancet. 2001;357:1601\u20138.","journal-title":"Lancet"},{"issue":"9982","key":"165_CR58","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","volume":"385","author":"SC Palmer","year":"2015","unstructured":"Palmer SC, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385(9982):2047\u201356.","journal-title":"Lancet."},{"key":"165_CR59","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1161\/01.HYP.0000203826.15076.4b","volume":"47","author":"S Ogawa","year":"2006","unstructured":"Ogawa S, et al. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension. 2006;47:699\u2013705.","journal-title":"Hypertension."},{"key":"165_CR60","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861\u20139.","journal-title":"N Engl J Med"},{"issue":"12","key":"165_CR61","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851\u201360.","journal-title":"N Engl J Med."},{"issue":"12","key":"165_CR62","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.2337\/diacare.26.12.3296","volume":"26","author":"S Andersen","year":"2003","unstructured":"Andersen S, et al. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care. 2003;26(12):3296\u2013302.","journal-title":"Diabetes Care."},{"issue":"4","key":"165_CR63","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.ijcard.2012.04.058","volume":"167","author":"H Takagi","year":"2013","unstructured":"Takagi H, et al. Effects of telmisartan on proteinuria or albuminuria: a meta-analysis of randomized trials. Int J Cardiol. 2013;167(4):1443\u20139.","journal-title":"Int J Cardiol."},{"issue":"3","key":"165_CR64","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/hr.2012.183","volume":"36","author":"T Yasuda","year":"2013","unstructured":"Yasuda T, et al. Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT). Hypertens Res. 2013;36(3):240\u20136.","journal-title":"Hypertens Res."},{"key":"165_CR65","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","volume":"106","author":"G Viberti","year":"2002","unstructured":"Viberti G, Wheeldon NM. MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators: microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106:672\u20138.","journal-title":"Circulation."},{"key":"165_CR66","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1185\/03007995.2012.731389","volume":"28","author":"X Zhang","year":"2012","unstructured":"Zhang X, et al. Efficacy and safety of valsartan in reducing blood pressure and albuminuria in Chinese patients with essential hypertension: a multicenter prospective open-label observational study. Curr Med Res Opin. 2012;28:1677\u201384.","journal-title":"Curr Med Res Opin."},{"issue":"7274","key":"165_CR67","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","volume":"321","author":"CE Mogensen","year":"2000","unstructured":"Mogensen CE, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274):1440\u20134.","journal-title":"BMJ."},{"key":"165_CR68","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","volume":"364","author":"H Haller","year":"2011","unstructured":"Haller H, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907\u201317.","journal-title":"N Engl J Med"},{"issue":"12","key":"165_CR69","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","volume":"54","author":"E Imai","year":"2011","unstructured":"Imai E, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54(12):2978\u201386.","journal-title":"Diabetologia."},{"key":"165_CR70","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1161\/HYPERTENSIONAHA.113.02855","volume":"63","author":"R Padwal","year":"2014","unstructured":"Padwal R, et al. Comparative effectiveness of olmesartan and other angiotensin receptor blockers in diabetes mellitus retrospective cohort study. Hypertension. 2014;63:977\u201383.","journal-title":"Hypertension."},{"key":"165_CR71","first-page":"25","volume":"2","author":"Yoshiyuki Hamamoto","year":"2011","unstructured":"Hamamoto Yoshiyuki, Koshiyama Hiroyuki. ROADMAP and ORIENTAL trials: the re-emergence of J-curve ghost? Jpn Clin Med. 2011;2:25\u20138.","journal-title":"Jpn Clin Med."},{"issue":"10","key":"165_CR72","first-page":"1017","volume":"32","author":"Gao-Zhong Huang","year":"2011","unstructured":"Huang Gao-Zhong, et al. Effects of telmisartan on insulin resistance and visceral fat distribution in Chinese hypertensive patients with obesity. Saudi Med J. 2011;32(10):1017\u201321.","journal-title":"Saudi Med J"},{"key":"165_CR73","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1210\/er.2005-0005","volume":"26","author":"T Kadowaki","year":"2005","unstructured":"Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439\u201351.","journal-title":"Endocr Rev"},{"key":"165_CR74","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2337\/diacare.27.1.247","volume":"27","author":"R Padwal","year":"2004","unstructured":"Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care. 2004;27:247\u201355.","journal-title":"Diabetes Care"},{"issue":"3","key":"165_CR75","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jash.2013.02.006","volume":"7","author":"Takagi","year":"2013","unstructured":"Takagi, et al. Telmisartan as a metabolic sartan: the first meta-analysis of randomized controlled trials in metabolic syndrome. J Am Soc Hypertens. 2013;7(3):229\u201335.","journal-title":"J Am Soc Hypertens."},{"issue":"8","key":"165_CR76","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s12325-011-0040-2","volume":"28","author":"Yutaka Mori","year":"2011","unstructured":"Mori Yutaka, et al. Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB Trial of Hypertension in Obese Patients with Hyperinsulinemia Assessed by Oral Glucose Tolerance Test (ATHLETE). Adv Ther. 2011;28(8):698\u2013706.","journal-title":"Adv Ther."},{"key":"165_CR77","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1291\/hypres.30.1205","volume":"30","author":"D Chujo","year":"2007","unstructured":"Chujo D, et al. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypertens Res. 2007;30:1205\u201310.","journal-title":"Hypertens Res."},{"issue":"1","key":"165_CR78","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1479164112444640","volume":"10","author":"Kazutoshi Murakami","year":"2013","unstructured":"Murakami Kazutoshi, et al. The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO). Diab Vasc Dis Res. 2013;10(1):93\u20136.","journal-title":"Diab Vasc Dis Res."},{"key":"165_CR79","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2337\/db07-0932","volume":"57","author":"SE Taksali","year":"2008","unstructured":"Taksali SE, et al. High visceral and low abdominal subcutaneous fat stores in the obese adolescent: a determinant of an adverse metabolic phenotype. Diabetes. 2008;57:367\u201371.","journal-title":"Diabetes"},{"issue":"12","key":"165_CR80","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1055\/s-0029-1237359","volume":"41","author":"R Fogari","year":"2009","unstructured":"Fogari R, et al. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. Horm Metab Res. 2009;41(12):893\u20138.","journal-title":"Horm Metab Res."},{"issue":"3","key":"165_CR81","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/met.2007.0002","volume":"5","author":"RD Brook","year":"2007","unstructured":"Brook RD, et al. Valsartan improves insulin sensitivity without altering vascular function in healthy overweight adults without the metabolic syndrome. Metab Syndr Relat Disord. 2007;5(3):255\u201361.","journal-title":"Metab Syndr Relat Disord."},{"issue":"6","key":"165_CR82","doi-asserted-by":"crossref","first-page":"e39930","DOI":"10.1371\/journal.pone.0039930","volume":"7","author":"GH Goossen","year":"2012","unstructured":"Goossen GH, et al. Valsartan improves adipose tissue function in humans with impaired glucose metabolism: a randomized placebo-controlled double-blind trial. PLoS One. 2012;7(6):e39930.","journal-title":"PLoS One."},{"issue":"1","key":"165_CR83","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40256-013-0004-9","volume":"13","author":"JB Park","year":"2013","unstructured":"Park JB, Sung KC, Kang SM, et al. Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb Study): an open-label observational study. Am J Cardiovasc Drugs. 2013;13(1):47\u201356.","journal-title":"Am J Cardiovasc Drugs."},{"key":"165_CR84","doi-asserted-by":"publisher","unstructured":"Conde-Carmona I, Cardona E. Open label study of the efficacy and safety of fimasartan 60\u00a0mg alone as initial treatment and its randomized escalation to fimasartan 120\u00a0mg or fimasartan 60\u00a0mg\/hydrochlorothiazide 12.5\u00a0mg in Mexican patients with essential hypertension grade 1 or 2. J Am Coll Cardiol. 2015;65(10_S). doi: 10.1016\/S0735-1097(15)61393-6 .","DOI":"10.1016\/S0735-1097(15)61393-6"},{"issue":"3\u20134","key":"165_CR85","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000360965","volume":"1","author":"C Kim","year":"2013","unstructured":"Kim C, Kim MY, Kang DR, et al. The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): rationale, design and participant characteristics. Pulse. 2013;1(3\u20134):177\u201385.","journal-title":"Pulse."},{"key":"165_CR86","unstructured":"Csiky B. The pleiotropic effects of losartan [Hungarian]. LAM. 2008;18(10):663\u201366."},{"issue":"12","key":"165_CR87","first-page":"831","volume":"90","author":"BL Hainer","year":"2014","unstructured":"Hainer BL, et al. Diagnosis, treatment, and prevention of gout. Am Fam Physician. 2014;90(12):831\u20136.","journal-title":"Am Fam Physician."},{"key":"165_CR88","doi-asserted-by":"crossref","unstructured":"Iwanaga T, et al. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporters. JPET. 2007;320:211\u20137.","DOI":"10.1124\/jpet.106.112755"},{"key":"165_CR89","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00005344-199608000-00012","volume":"28","author":"JP Fauvel","year":"1996","unstructured":"Fauvel JP, et al. Effects of losartan on renal function in patients with essential hypertension. J Cardiovasc Pharmacol. 1996;28:259\u201363.","journal-title":"J Cardiovasc Pharmacol."},{"key":"165_CR90","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0149-2918(00)83062-3","volume":"22","author":"AJ Manolis","year":"2000","unstructured":"Manolis AJ, et al. Effects of losartan and candesartan monotherapy and losartan\/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension: Losartan Trial Investigators. Clin Ther. 2000;22:1186\u2013203.","journal-title":"Clin Ther."},{"key":"165_CR91","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF00266358","volume":"42","author":"M Nakashima","year":"1992","unstructured":"Nakashima M, et al. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 1992;42:333\u20135.","journal-title":"Eur J Clin Pharmacol."},{"issue":"5","key":"165_CR92","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/j.1552-4604.1998.tb04450.x","volume":"38","author":"BE Ilson","year":"1998","unstructured":"Ilson BE, et al. The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension. J Clin Pharmacol. 1998;38(5):437\u201341.","journal-title":"J Clin Pharmacol."},{"key":"165_CR93","first-page":"79","volume":"6","author":"M Nakamura","year":"2014","unstructured":"Nakamura M, et al. Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes. Clin Pharmacol. 2014;6:79\u201386.","journal-title":"Clin Pharmacol."},{"issue":"12","key":"165_CR94","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/CIRCULATIONAHA.109.864199","volume":"121","author":"M Bohm","year":"2010","unstructured":"Bohm M, Baumhakel M, Teo K, et al. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial\/Telmisartan Randomized Assessment Study in ACE intolerant subjects with cardiovascular Disease (ONTARGET\/TRANSCEND) trials. Circulation. 2010;121(12):1439\u201346.","journal-title":"Circulation."},{"key":"165_CR95","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000351696","volume":"125","author":"M Doumas","year":"2013","unstructured":"Doumas M, et al. Combined antihypertensive therapy and sexual dysfunction: terra incognita. Cardiology. 2013;125:232\u20134.","journal-title":"Cardiology"},{"issue":"1","key":"165_CR96","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0090-4295(00)00881-5","volume":"57","author":"AJ Becker","year":"2001","unstructured":"Becker AJ, et al. Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence. Urology. 2001;57(1):193\u20138.","journal-title":"Urology."},{"key":"165_CR97","doi-asserted-by":"crossref","unstructured":"Viigimaa M, et al. (eds). Erectile dysfunction in hypertension and cardiovascular disease: a guide for clinicians. Berlin: Springer; 2014.","DOI":"10.1007\/978-3-319-08272-1"},{"key":"165_CR98","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12471-013-0482-z","volume":"22","author":"MPJ Nicolai","year":"2014","unstructured":"Nicolai MPJ, et al. A review of the positive and negative effects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice. Neth Heart J. 2014;22:11\u20139.","journal-title":"Neth Heart J"},{"issue":"3","key":"165_CR99","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1124\/jpet.108.140533","volume":"327","author":"M Baumhakel","year":"2008","unstructured":"Baumhakel M, et al. Improvement of endothelial function of the corpus cavernosum in apolipoprotein E knockout mice treated with irbesartan. J Pharmacol Exp Ther. 2008;327(3):692\u20138.","journal-title":"J Pharmacol Exp Ther."},{"issue":"3","key":"165_CR100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2220\/biomedres.35.215","volume":"35","author":"S Shimizu","year":"2014","unstructured":"Shimizu S. Effect of an angiotensin II receptor blocker and a calcium channel blocker on hypertension associated penile dysfunction in a rat model. Biomed Res. 2014;35(3):215\u201321.","journal-title":"Biomed Res."},{"key":"165_CR101","doi-asserted-by":"crossref","unstructured":"Della Chiesa A, et al. Sexual activity in hypertensive men. J Hum Hypertens. 2003;17(8):515\u201321.","DOI":"10.1038\/sj.jhh.1001580"},{"key":"165_CR102","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/08038020310021967","volume":"2","author":"R Dusing","year":"2003","unstructured":"Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl. 2003;2:29\u201334.","journal-title":"Blood Press Suppl."},{"issue":"1","key":"165_CR103","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0895-7061(00)01214-0","volume":"14","author":"R Fogari","year":"2001","unstructured":"Fogari R, Zoppi A, Poletti L, et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens. 2001;14(1):27\u201331.","journal-title":"Am J Hypertens."},{"issue":"3","key":"165_CR104","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00228-002-0456-3","volume":"58","author":"R Fogari","year":"2002","unstructured":"Fogari R, et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol. 2002;58(3):177\u201380.","journal-title":"Eur J Clin Pharmacol."},{"issue":"6","key":"165_CR105","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/ijir.2012.4","volume":"24","author":"Y Chen","year":"2012","unstructured":"Chen Y, Cui S, Lin H, et al. Losartan improves erectile dysfunction in diabetic patients: a clinical trial. Int J Impot Res. 2012;24(6):217\u201320.","journal-title":"Int J Impot Res."},{"issue":"5","key":"165_CR106","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00000441-200105000-00006","volume":"321","author":"JL Llisterri","year":"2001","unstructured":"Llisterri JL, et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci. 2001;321(5):336\u201341.","journal-title":"Am J Med Sci."},{"key":"165_CR107","doi-asserted-by":"crossref","unstructured":"Baumh\u00e4kel M, et al. Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. Int J Impot Res. 2008;20(5):493\u2013500.","DOI":"10.1038\/ijir.2008.28"},{"issue":"11","key":"165_CR108","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/j.1464-410X.2012.11098.x","volume":"110","author":"RL Segal","year":"2012","unstructured":"Segal RL, et al. Irbesartan promotes erection recovery after nerve-sparing radical retropubic prostatectomy: a retrospective long-term analysis. BJU Int. 2012;110(11):1782\u20136.","journal-title":"BJU Int."},{"key":"165_CR109","doi-asserted-by":"crossref","unstructured":"Elias MF, Wolf PA, d\u2019Agostino RB, et al. Untreated blood pressure levels is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol. 1993;138:353\u201364","DOI":"10.1093\/oxfordjournals.aje.a116868"},{"key":"165_CR110","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/01.HYP.31.3.780","volume":"31","author":"L Kilander","year":"1998","unstructured":"Kilander L, Nyman H, Boberg M, et al. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension. 1998;31:780\u20136.","journal-title":"Hypertension"},{"key":"165_CR111","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0197-4580(00)00096-8","volume":"21","author":"LJ Launer","year":"2000","unstructured":"Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21:49\u201355.","journal-title":"Neurobiol Aging"},{"key":"165_CR112","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(96)90608-X","volume":"347","author":"I Skoog","year":"1996","unstructured":"Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347:1141\u20135.","journal-title":"Lancet"},{"key":"165_CR113","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1212\/WNL.53.9.1948","volume":"53","author":"C Tzourio","year":"1999","unstructured":"Tzourio C, Dufouil C, Ducimetiere P, et al. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Neurology. 1999;53:1948\u201352.","journal-title":"Neurology"},{"key":"165_CR114","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1212\/01.wnl.0000279520.59792.fe","volume":"69","author":"MM Mielke","year":"2007","unstructured":"Mielke MM, Rosenberg PB, Tschanz J, et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology. 2007;69:1850\u20138.","journal-title":"Neurology"},{"key":"165_CR115","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.clineuro.2008.10.006","volume":"111","author":"F Roselli","year":"2009","unstructured":"Roselli F, Tartaglione B, Federico F, et al. Rate of MMSE score change in Alzheimer\u2019s disease: influence of education and vascular risk factors. Clin Neurol Neurosurg. 2009;111:327\u201330.","journal-title":"Clin Neurol Neurosurg"},{"key":"165_CR116","doi-asserted-by":"crossref","first-page":"b5465","DOI":"10.1136\/bmj.b5465","volume":"340","author":"N-C Li","year":"2010","unstructured":"Li N-C, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010;340:b5465.","journal-title":"BMJ"},{"key":"165_CR117","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nbd.2014.04.018","volume":"68","author":"B Ongali","year":"2014","unstructured":"Ongali B, et al. Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer\u2019s disease model. Neurobiol Dis. 2014;68:126\u201336.","journal-title":"Neurobiol Dis."},{"issue":"3","key":"165_CR118","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/ajh.2010.241","volume":"24","author":"N Pelisch","year":"2011","unstructured":"Pelisch N, et al. Blockade of AT1 receptors protects the blood\u2013brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats. Am J Hypertens. 2011;24(3):362\u20138.","journal-title":"Am J Hypertens."},{"key":"165_CR119","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jjcc.2012.08.004","volume":"60","author":"Takuya Kishi","year":"2012","unstructured":"Kishi Takuya, et al. Telmisartan protects against cognitive decline via up-regulation of brain-derived neurotrophic factor\/tropomyosin-related kinase B in hippocampus of hypertensive rats. J Cardiol. 2012;60:489\u201394.","journal-title":"J Cardiol."},{"key":"165_CR120","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.pharep.2013.11.002","volume":"66","author":"D Wincewicz","year":"2014","unstructured":"Wincewicz D, Braszko JJ. Telmisartan attenuates cognitive impairment caused by chronic stress in rats. Pharmacol Rep. 2014;66:436\u201341.","journal-title":"Pharmacol Rep."},{"key":"165_CR121","doi-asserted-by":"crossref","unstructured":"Hanon O, et al. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study. J Hypertens. 2008;26(8):1642\u201350.","DOI":"10.1097\/HJH.0b013e328301a280"},{"key":"165_CR122","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1447-0594.2011.00746.x","volume":"12","author":"Kazumasa Kume","year":"2012","unstructured":"Kume Kazumasa, et al. Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer\u2019s disease. Geriatr Gerontol Int. 2012;12:207\u201314.","journal-title":"Geriatr Gerontol Int."},{"key":"165_CR123","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02085265?term=sartan-ad&rank=1"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-016-0165-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-016-0165-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-016-0165-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T13:24:52Z","timestamp":1654521892000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-016-0165-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,3]]},"references-count":123,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["165"],"URL":"https:\/\/doi.org\/10.1007\/s40256-016-0165-4","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,3]]}}}